Literature DB >> 8124053

Nephrotoxicity of cyclosporine in humans: effect of cyclosporine on glomerular filtration and proximal tubular reabsorption.

P Heering1, P Schadewaldt, D Bach, B Grabensee.   

Abstract

The chronic nephrotoxic effects of cyclosporine (CsA) include proximal tubular atrophy and vacuolization. This study investigated the effect of CsA on renal hemodynamics and segmental electrolyte transport in CsA-treated patients. The clearance of inulin (CIn) and PAH para-amino-hippuric acid (CPAH) was determined; proximal tubular function was studied using a lithium clearance method and calculating tubular phosphate reabsorption per milliliter of glomerular filtrate (TP/CIn). Twenty patients without renal disease were investigated: ten treated with CsA because of nonrenal grafting (group 1) and ten healthy volunteers (group 2). The results obtained were compared with those from 20 renal allograft recipients, of whom ten were treated with CsA and methylprednisolone (group 3) and ten with azathioprine and methylprednisolone (group 4). CIn and CPAH were significantly impaired in patients treated with CsA. No significant impairment of lithium clearance as induced by CsA was observed. The fractional excretion of lithium was slightly increased in patients treated with CsA compared to their respective controls. TP/CIn was lower in graft recipients compared to controls; no impairment of phosphate reabsorption as induced by CsA was found. The fractional tubular excretion of lithium was slightly increased compared to controls, rising evidence that proximal tubular reabsorption of lithium was decreased. Tubular reabsorption of phosphate was not impaired. The decrease in glomerular filtration and renal perfusion during chronic treatment with CsA was accompanied by a reduced proximal reabsorptive capacity, as was shown by lithium clearance. Our data do not support the hypothesis that functional parameters of the proximal tubular system can be used as indicators of CsA-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124053     DOI: 10.1007/bf00180033

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  19 in total

1.  The use of lithium clearance measurements to assess renal tubular function in experimental and clinical cyclosporine nephrotoxicity.

Authors:  P H Whiting; D J Propper; J G Simpson; J McKay; M C Jones; G R Catto
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

Review 2.  Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water.

Authors:  K Thomsen
Journal:  Nephron       Date:  1984       Impact factor: 2.847

3.  Chronic injury of human renal microvessels with low-dose cyclosporine therapy.

Authors:  B D Myers; L Newton; C Boshkos; J A Macoviak; W H Frist; G C Derby; M G Perlroth; R K Sibley
Journal:  Transplantation       Date:  1988-11       Impact factor: 4.939

4.  Cimetidine improves the reliability of creatinine as a marker of glomerular filtration.

Authors:  L B Hilbrands; M A Artz; J F Wetzels; R A Koene
Journal:  Kidney Int       Date:  1991-12       Impact factor: 10.612

5.  Influence of ciclosporin A on renal tubular function after kidney transplantation.

Authors:  P Heering; B Grabensee
Journal:  Nephron       Date:  1991       Impact factor: 2.847

6.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

7.  Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling.

Authors:  H Stark; B Eisenstein; M Tieder; A Rachmel; G Alpert
Journal:  Nephron       Date:  1986       Impact factor: 2.847

8.  Postnatal development of tubular phosphate reabsorption.

Authors:  J Brodehl; K Gellissen; H P Weber
Journal:  Clin Nephrol       Date:  1982-04       Impact factor: 0.975

9.  [Kidney function of patients with healthy kidneys during cyclosporin treatment].

Authors:  P Heering; B Kutkuhn; G Kreuzpaintner; T Reinhard; R Sundmacher; B Grabensee
Journal:  Klin Wochenschr       Date:  1991-11-26

10.  Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients.

Authors:  K J Berg; H Holdaas; L Endresen; P Fauchald; A Hartmann; T Pran; D Solbu
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

View more
  6 in total

1.  Enzymatic markers of cyclosporine nephrotoxicity in patients after renal transplantation.

Authors:  Z Marchewka; J Kuźniar; A Długosz
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

2.  [Tubulointerstitial nephritis with uveitis (TINU) syndrome. A relatively rare rheumatological differential diagnosis with unexplained uveitis].

Authors:  U Häusler; B Guminski; U Helmchen; K Kisters; C Heinz; J Braun
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

Review 3.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database.

Authors:  Iku Niinomi; Saki Oyama; Ayaka Inada; Tomohito Wakabayashi; Tatsuya Iida; Hiroko Kambara; Mayako Uchida; Yukako Sano; Keiko Hosohata
Journal:  Cureus       Date:  2022-09-20

Review 5.  Ferroptosis: A Potential Therapeutic Target in Acute Kidney Injury.

Authors:  Keiko Hosohata; Tanisorn Harnsirikarn; Susama Chokesuwattanaskul
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

6.  Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A-induced nephrotoxicity in rats.

Authors:  Yong Chia Tan; Munavvar Abdul Sattar; Ahmad F Ahmeda; Nurzalina Abdul Karim Khan; Vikneswaran Murugaiyah; Ashfaq Ahmad; Zurina Hassan; Gurjeet Kaur; Mohammed Hadi Abdulla; Edward James Johns
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.